Solural Pharma ApS enters into an exclusive license agreement with Dyna Therapeutics Co., Ltd, Korea to develop and commercialize SOL-804 for treatment of metastatic castration resistant prostate cancer. SOL-804 is based on the proprietary Solural Lymphatic Targeting Technology.
- Updated Manufacturing and Importation Authorisation February 13, 2018
- Solural Pharma gets a European patent August 9, 2017
- Ascelia Pharma AB acquires Oncoral Pharma ApS June 30, 2017